Gender disparities in coronavirus disease 2019 clinical trial leadership
| Autor: | Syed Arefinul Haque, Chloe Orkin, Jennifer Manne-Goehler, Maimuna S. Majumder, Paul E. Sax, Muge Cevik, Krutika Kuppalli |
|---|---|
| Přispěvatelé: | University of St Andrews. School of Medicine, University of St Andrews. Infection and Global Health Division |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Male medicine.medical_specialty 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) 030106 microbiology Sexism Breast Neoplasms 03 medical and health sciences 0302 clinical medicine Breast cancer SDG 3 - Good Health and Well-being Emerging infections RA0421 RA0421 Public health. Hygiene. Preventive Medicine Pandemic medicine Humans Women 030212 general & internal medicine Sex Ratio Clinical Trials as Topic Novel coronavirus SDG 5 - Gender Equality business.industry SARS-CoV-2 Gender distribution Type 2 Diabetes Mellitus COVID-19 Gender General Medicine 3rd-DAS medicine.disease Research Personnel Clinical trial Coronavirus Leadership Infectious Diseases Diabetes Mellitus Type 2 Family medicine Commentary Female business |
| Zdroj: | Clinical Microbiology and Infection |
| Popis: | Objectives To compare the gender distribution of clinical trial leadership in coronavirus disease 2019 (COVID-19) clinical trials. Methods We searched https://clinicaltrials.gov/ and retrieved all clinical trials on COVID-19 from 1 January 2020 to 26 June 2020. As a comparator group, we have chosen two fields that are not related to emerging infections and infectious diseases: and considered not directly affected by the pandemic: breast cancer and type 2 diabetes mellitus (T2DM) and included studies within the aforementioned study period as well as those registered in the preceding year (pre-study period: 1 January 2019 to 31 December 2019). Gender of the investigator was predicted using the genderize.io application programming interface. The repository of the data sets used to collect and analyse the data are available at https://osf.io/k2r57/. Results Only 27.8% (430/1548) of principal investigators among COVID-19-related studies were women, which is significantly different compared with 54.9% (156/284) and 42.1% (56/133) for breast cancer (p 0.05). ConclusionWe demonstrate that less than one-third of COVID-19-related clinical trials are led by women, half the proportion observed in non-COVID-19 trials over the same period, which remained similar to the pre-study period. These gender disparities during the pandemic may not only indicate a lack of female leadership in international clinical trials and involvement in new projects but also reveal imbalances in women's access to research Postprint |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|